Erbin Dai
Affiliation confirmed via AI analysis of OpenAlex, ORCID, and web sources.
Researcher
Faculty Researcher
Research Areas
Biomedical Subjects
Links
Biography and Research Information
OverviewAI-generated summary
Erbin Dai's research focuses on the development of novel anticoagulants and anti-thrombotic agents, with an emphasis on biomaterials and glycomimetics. Dai has investigated the synthesis and application of sulfated poly-amido-saccharides (sulPASs) as anticoagulants, demonstrating their efficacy both in vitro and in vivo. Further work includes the design of ultralow molecular weight heparin variants that exhibit resistance to heparanase biodegradation, aiming to improve therapeutic longevity.
In addition to anticoagulant development, Dai's work has explored targeted inhibition of P-selectin through PSGL-1 glycopeptide analogues and glycomimetics, showing potential to reduce thrombus burden without compromising hemostasis. This research also extends to the creation of rechargeable anti-thrombotic coatings for blood-contacting medical devices. Dai's recent publications also touch upon the association between the gut microbiome and antituberculosis drug-induced liver injury, and the protective effects of anlotinib on radiation lung injury through immune microenvironment regulation, alongside challenges in measuring drug-induced liver injury biomarkers on a liver-on-a-chip platform.
Metrics
- h-index: 26
- Publications: 76
- Citations: 1,761
Selected Publications
-
Challenges and solutions in measuring commonly used biomarkers for drug-induced liver injury in a liver-on-a-chip platform (2025)
Collaboration Network
Top Collaborators
- Challenges and solutions in measuring commonly used biomarkers for drug-induced liver injury in a liver-on-a-chip platform
- Challenges and solutions in measuring commonly used biomarkers for drug-induced liver injury in a liver-on-a-chip platform
- Challenges and solutions in measuring commonly used biomarkers for drug-induced liver injury in a liver-on-a-chip platform
- Challenges and solutions in measuring commonly used biomarkers for drug-induced liver injury in a liver-on-a-chip platform
- Challenges and solutions in measuring commonly used biomarkers for drug-induced liver injury in a liver-on-a-chip platform
- Challenges and solutions in measuring commonly used biomarkers for drug-induced liver injury in a liver-on-a-chip platform
- Challenges and solutions in measuring commonly used biomarkers for drug-induced liver injury in a liver-on-a-chip platform
- Challenges and solutions in measuring commonly used biomarkers for drug-induced liver injury in a liver-on-a-chip platform
- Challenges and solutions in measuring commonly used biomarkers for drug-induced liver injury in a liver-on-a-chip platform
- Challenges and solutions in measuring commonly used biomarkers for drug-induced liver injury in a liver-on-a-chip platform
- Challenges and solutions in measuring commonly used biomarkers for drug-induced liver injury in a liver-on-a-chip platform
- Challenges and solutions in measuring commonly used biomarkers for drug-induced liver injury in a liver-on-a-chip platform
- Challenges and solutions in measuring commonly used biomarkers for drug-induced liver injury in a liver-on-a-chip platform
- Challenges and solutions in measuring commonly used biomarkers for drug-induced liver injury in a liver-on-a-chip platform
Similar Researchers
Based on overlapping research topics